Ultimovacs Management
Management criteria checks 3/4
Ultimovacs' CEO is Carlos de Sousa, appointed in Jun 2020, has a tenure of 3.83 years. total yearly compensation is NOK6.50M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth €15.39K. The average tenure of the management team and the board of directors is 4.5 years and 7.3 years respectively.
Key information
Carlos de Sousa
Chief executive officer
kr6.5m
Total compensation
| CEO salary percentage | 74.5% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.5yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr7m | kr5m | -kr189m |
| Sep 30 2023 | n/a | n/a | -kr204m |
| Jun 30 2023 | n/a | n/a | -kr186m |
| Mar 31 2023 | n/a | n/a | -kr165m |
| Dec 31 2022 | kr8m | kr5m | -kr168m |
| Sep 30 2022 | n/a | n/a | -kr148m |
| Jun 30 2022 | n/a | n/a | -kr153m |
| Mar 31 2022 | n/a | n/a | -kr168m |
| Dec 31 2021 | n/a | n/a | -kr165m |
| Sep 30 2021 | n/a | n/a | -kr138m |
| Jun 30 2021 | n/a | n/a | -kr126m |
| Mar 31 2021 | n/a | n/a | -kr124m |
| Dec 31 2020 | kr5m | kr3m | -kr121m |
Compensation vs Market: Carlos's total compensation ($USD591.81K) is above average for companies of similar size in the German market ($USD401.52K).
Compensation vs Earnings: Carlos's compensation has been consistent with company performance over the past year.
CEO
Carlos de Sousa (65 yo)
3.8yrs
Tenure
kr6,504,000
Compensation
Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3.8yrs | kr6.50m | 0.076% NOK 15.4k | |
| Chief Financial Officer | 8.4yrs | kr4.41m | no data | |
| Head of Research | no data | kr2.57m | no data | |
| Chief Technology Officer | 3.2yrs | kr2.92m | no data | |
| Head of Investor Relations & ESG | 2.5yrs | kr2.31m | no data | |
| Chief Medical Officer | 7.8yrs | kr4.29m | no data | |
| Head of Clinical Operations | 6.7yrs | kr2.71m | no data | |
| Head of Project Coordination | 6.7yrs | kr2.50m | no data | |
| Chief Business Officer | 3.3yrs | kr4.43m | no data | |
| Head of Regulatory Affairs & QA | 2.5yrs | kr2.37m | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Chief Innovation Officer | 5.3yrs | no data | no data |
4.5yrs
Average Tenure
Experienced Management: 7UM's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Deputy Board member | no data | kr250.00k | no data | |
| Independent Chairman | 13.3yrs | kr450.00k | 0.015% NOK 3.1k | |
| Independent Director | 9.3yrs | kr320.00k | 0.27% NOK 54.0k | |
| Independent Director | 5.3yrs | kr250.00k | 0.019% NOK 3.8k | |
| Independent Director | 5.3yrs | kr250.00k | 0.019% NOK 3.9k | |
| Director | 9.3yrs | kr250.00k | no data | |
| Independent Director | 3.4yrs | kr290.00k | no data |
7.3yrs
Average Tenure
60yo
Average Age
Experienced Board: 7UM's board of directors are considered experienced (7.3 years average tenure).